Phibro Animal Health Executive Compensation (FY26)
PAHC · Executive and director compensation, fiscal 2024 to 2026
The Phibro Animal Health brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Data as of September 26, 2026Latest filing (DEF 14A): September 18, 2026
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
122 figures on this page: 119 cited to the filing that reported them, 3 calculated from figures it prints. See the citations
What changed from fiscal 2025 to fiscal 2026
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Daniel Bendheim: $1,119,780 → $1,120,094 (0.0% higher)
CEO pay ratio: 95:1 → 74:1 (22.1% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Phibro Animal Health's chief executive and what were they paid?
Daniel Bendheim was paid $1,120,094 in total compensation as President and Chief Executive Officer for fiscal 2026. Bendheim's total was 0.0% higher than the $1,119,780 reported for fiscal 2025.
What was Phibro Animal Health's say-on-pay result?
Shareholders recorded 99.5% support for the say-on-pay proposal at the meeting held November 4, 2025 for fiscal 2025.
What is Phibro Animal Health's chief executive pay ratio?
For fiscal 2026, the company reported a chief executive pay ratio of 74:1, against median employee compensation of $71,100.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Larry Miller Chief Operating Officer | ◇ | ◇ | ◇ | — | ◇ | ◇ | ◇ | ◇ |
Glenn David Chief Financial Officer | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Daniel Bendheim President and Chief Executive Officer | ◇ | ◇ | — | — | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Jack Bendheim Chairman of the Board and Executive Chairman | ◇ | ◇ | — | — | ◇ | ◇ | ◇ | ◇ |
Larry Miller Chief Operating Officer | ◇ | ◇ | — | — | ◇ | ◇ | ◇ | ◇ |
Glenn David Chief Financial Officer | ◇ | ◇ | — | — | ◇ | — | ◇ | ◇ |
Daniel Bendheim President and Chief Executive Officer | ◇ | ◇ | — | — | ◇ | ◇ | ◇ | ◇ |
Judith Weinstein Senior Vice President, General Counsel and Corporate Secretary | ◇ | ◇ | — | — | ◇ | ◇ | ◇ | ◇ |
Fiscal 2026
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Jack Bendheim Chairman of the Board and Executive Chairman | ◇ | — | ◇ | — | ◇ | ◇ | ◇ | ◇ |
Larry Miller Chief Operating Officer | ◇ | ◇ | ◇ | — | ◇ | ◇ | ◇ | ◇ |
Glenn David Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Daniel Bendheim President and Chief Executive Officer | ◇ | — | ◇ | — | ◇ | ◇ | ◇ | ◇ |
Judith Weinstein Senior Vice President, General Counsel and Corporate Secretary | ◇ | — | ◇ | — | ◇ | ◇ | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2026 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Daniel Bendheim | RSU | ◇ | ◇ | — | — |
| Glenn David | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Larry Miller | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Judith Weinstein | RSU | ◇ | ◇ | — | — |
| Jack Bendheim | RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2026
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Carol A. Wrenn | ◇ | — | — | — | — | — | ◇ |
Sam Gejdenson | ◇ | — | — | — | — | — | ◇ |
Alejandro Bernal | ◇ | — | — | — | — | — | ◇ |
E. Thomas Corcoran | ◇ | — | — | — | — | — | ◇ |
Mary Lou Malanoski | ◇ | — | — | — | — | — | ◇ |
Joyce J. Lee | ◇ | — | — | — | — | — | ◇ |
Jack C. Bendheim and Daniel M. Bendheim served on the board in fiscal 2026 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Total board retainer | ◇ |
| Audit committee member | ◇ |
| Compensation committee member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | November 4, 2025 | = | ◇ | ◇ | ◇ |
| 2022 | November 7, 2022 | = | ◇ | ◇ | ◇ |
| 2019 | November 4, 2019 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Velarion Pro: every company page, peer tools and exports, one seat
One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
What this page does not include
Everything above is a fact Phibro Animal Health disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
122 figures on this page: 119 cited to the filing that reported them, 3 calculated from figures it prints.
119 cited to the filing
3 calculated from the filing
Documents cited
- 0001104659-26-1089392026 Director Compensation · 2026 Summary Compensation Table · CEO PAY RATIO
- 0001104659-25-107064
- 0001104659-22-115975ITEM 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
- 0001104659-19-060110
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Phibro Animal Health executive compensation, FY2024–FY2026.” https://intel.velarion.ai/comp/PAHC (accessed 2026).
Short form: data: Velarion
The Phibro Animal Health brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Phibro Animal Health and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}